Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and conventional intensity-modulated radiotherapy in locally advanced non-small-cell lung cancer: a retrospective study

Daquan Wang, Nan Bi, Tao Zhang, Zongmei Zhou, Zefen Xiao, Jun Liang, Dongfu Chen, Zhouguang Hui, Jima Lv, Xiaozhen Wang, Xin Wang, Lei Deng, Wenqing Wang, Jingbo Wang, Chunyu Wang, Xiaotong Lu, Kunpeng Xu, Linfang Wu, Wenji Xue, Qinfu Feng* and Luhua Wang*

Abstract

Background: Consistent results are lacking as regards the comparative effectiveness of simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) versus conventional intensity-modulated radiotherapy in patients with locally advanced non-small-cell lung cancer (LA-NSCLC). Therefore, we conducted a retrospective analysis to demonstrate the role of SIB-IMRT for patients.

Methods: Patients who had histologically confirmed NSCLC, stage III disease and received thoracic IMRT between 2014 and 2016 were retrospectively reviewed. The survival, toxicities and dose to organs at risk (OAR) were compared among patients irradiated with different techniques. The SIB-IMRT plans were designed to deliver 45–59.4 Gy (median: 50.4 Gy) to PTV while simultaneously delivering 50-70 Gy (median: 59.92 Gy) to PGTV. As for conventional IMRT plans, a total dose of 50-70 Gy (median: 60 Gy) was delivered to PTV.

Results: 426 patients with stage III NSCLC were eligible for analysis, including 128 with SIB-IMRT and 298 with conventional IMRT. The SIB-IMRT group had more stage IIIB disease (69.5% vs. 53%, \( P = 0.002 \)), larger planning treatment volumes (median: 504 ml vs. 402 ml, \( P<0.001 \)), and a larger planning treatment volume/volume of lung ratio (median, 0.18 vs. 0.12, \( P<0.001 \)). The median OS of the SIB-IMRT and conventional IMRT groups were 34.5 and 31.7 months, with the 2-year rate of 60.4 and 59%, respectively \( (P = 0.797) \). No difference in PFS, LRFS or DMFS was observed between the two techniques. Patients treated with SIB-IMRT got similar lung and esophageal toxicities versus those with conventional IMRT.

Conclusions: SIB-IMRT may be an effective and safe option for patients with locally advanced NSCLC, especially for those with large mass or wide lymph node metastasis.

Keywords: Non-small cell lung cancer, Simultaneous integrated boost, Intensity-modulated radiotherapy, Survival, Toxicity

* Correspondence: qinfufeng19@163.com, whwq@yahoo.com
Department of Radiation Oncology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Approximately 30% of patients with non-small cell lung cancer (NSCLC) belong to the locally advanced stage [1], and definitive thoracic radiotherapy concurrently with chemotherapy is the standard care [2] [3]. However, in clinic, certain patients with large mass, extensive lymph node metastasis, or poor lung function, often failed to tolerate definitive radiotherapy because of high risk of treatment-related toxicities. Radiation-induced pneumonitis (RP) is the most important dose-limiting toxicity. The incidence of symptomatic RP was reported to be about 20–30% in NSCLC patients treated with concurrent chemoradiotherapy [4, 5]. It might result in a decreased treatment intensification, such as interruption of radiotherapy or low tolerance of chemotherapy.

Intensity-modulated radiation technique (IMRT) has been proven to improve tumor control and to reduce lung toxicities and lower cardiac doses [5, 6]. Currently, the radiation dose delivered to gross tumor volume (GTV) and clinical target volume (CTV) are generally same. In the trial of RTOG 0617, a homogeneous dose of 74 Gy to both gross and subclinical diseases did not improve OS. On the contrary, an increased death risk by 38% was observed, which might due to increased radiation-induced toxicities [7].

In the modern area, there is a growing interest in the delivery of IMRT-based simultaneously integrated boost (SIB). This approach could simultaneously confer a radical dose to the gross tumor while a relatively lower dose to the subclinical disease, which consequently might improve treatment tolerance for patients with complex conditions such as large mass, extensive lymph node metastasis, or poor lung function. Although previous study reported that a conventionally fractionated dose of 50 Gy may be sufficient to eradicate subclinical disease [8], the clinical effectiveness of SIB-IMRT for LA-NSCLC remains to be confirmed, due to the respiration introduces complexity and the potential failures of the treatment margin.

In the present study, SIB-IMRT-based lung sparing technique was used to confer radical radiation to the gross tumor volume, while limiting lung irradiation dose. We aimed to compare the efficacy and toxicity profile between SIB-IMRT and conventional IMRT.

Methods

Patients

This was a retrospective study. Patients with histologically proven stage III NSCLC (American Joint Committee on Cancer, 7th edition) and receiving thoracic IMRT at our center between January 2014 and December 2016 were included. The procedure of data analysis was shown in Fig. 1. The inclusion criteria were histologically/cytologically confirmed NSCLC, older than age 18 at the time of diagnosis, stage III disease, Karnofsky performance status (KPS) score ≥70, and receiving thoracic IMRT. The enrolled patients had to have radiotherapy as a definitive form of treatment. Patients with radiation dose <50 Gy, prior thoracic radiotherapy or surgery, or other coexisting primary tumors were excluded. The study was approved by the local institutional review board.

Treatment strategy

All the patients underwent computed tomograph (CT)-based simulation with 5-mm slice thickness. A head-neck-shoulder mask or chest mask was used to immobilize patients in the supine position during simulation. The scanned area extended from the laryngeal prominence to the bottom of the L2 vertebral body. Four-dimensional simulation was used for selected patients with peripheral or lower lobe lesions. The scanned images were transferred to a three-dimensional (3D) planning system (Philips, Pinnacle 9.0; Netherlands) (Fig. 2).

All of the patients underwent intensity-modulated radiotherapy (IMRT) [4]. The gross tumor volume (GTV) included the primary disease as well as any involved regional lymph nodes, which were defined as those with a short-axis diameter of at least 1 cm on the CT scan or with a short-axis diameter of less than 1 cm but with high fluorodeoxyglucose (FDG) uptake on the Positron emission tomography (PET)-CT scan. The clinical target volume (CTV) was created by expanding the GTV by 0.6–0.8 cm, as well as ipsilateral hilum and mediastinal nodal stations involved. The planning target volume (PTV) was generated by a uniform 0.5 cm expansion around the CTV. For patients treated with SIB-IMRT, the planning gross tumor volume (PGTV)

Fig. 1 The procedure of data analysis
was generated by a uniform 0.5 cm expansion around the GTV.

Radiation therapy was delivered by 6MV X-rays from a linear accelerator (Elekta, Synergy, Sweden; Elekta, VersaHD, Sweden; Varian, Novalis, United States; Varian, Unique, United States). The cone-beam computed tomograph (CBCT) scans was used in most patients for positioning. It was repeated before each treatment in the first week, then performed once a week. Electronic portal imaging device (EPID) was used in a small proportion of patients and it was conducted once a week. For patients treated with conventional IMRT, the median prescribed dose was 60Gy/30f (range: 50.0–70.0Gy, in 25–35 fractions) (Median BED10 72Gy, range: 60–84Gy) to PTV. As for patients with SIB-IMRT, the median prescribed dose was 59.92Gy/28f (range: 50.0–70.0Gy, in 25–33 fractions) (Median BED10 72.74Gy, range: 60–84Gy) to PGTV, and 50.4Gy/28f (range, 45–59.4Gy, in 25–33 fractions) (Median BED10 59.47Gy, range: 53.1–70.1Gy) to PTV. It should be noted that the PTV in the SIB group contain the PGTV. All the patients received concurrent or sequential platinum-based doublet chemotherapy. The mean dose to the lungs (MLD) should optimally be ≤17Gy and not exceed 20Gy; the lung volumes minus GTV receiving more than 20Gy (V20) and 30Gy (V30) were limited to less than 30 and 20%, respectively. The heart volumes receiving more than 30Gy (V30) and 40Gy (V40), were limited to less than 40 and 30%, respectively. The esophageal volume receiving more than 50Gy (V50) was limited to less than 50%. The maximal dose for spinal cord PRV (5 mm) was 45Gy.

**Evaluation and follow-up**

Pre-treatment evaluation included full medical histories and physical examinations, laboratory investigations, such as complete blood cell counts (CBC) and chemistries, electrocardiographs (ECGs), and pulmonary function tests. The following examinations were performed to specify the TNM stage of patients: chest and abdominal CTs, brain MRI/CTs, bronchoscopies, and radionuclide bone scans. PET-CTs were recommended but not mandatory.

All patients underwent CBC and blood chemistry examinations once a week during the treatment period. After discharge from the hospital, the patients were followed up every 3 months from hospital medical records and/or by phone. The follow-up evaluations consisted of patient history, a physical examination, and a thoracic CT at intervals of 3 months for 2 years and then 6 to 12 months for 3 years, or earlier if clinically indicated. Other imaging examinations were obtained when recurrence was suspected.

**Definition of endpoints**

The endpoints included overall survival (OS), progression-free survival (PFS), locoregional recurrence-free survival (LRFS), distant metastasis-free survival (DMFS) and treatment-related toxicity. OS was calculated from the date of initial treatment to death or last follow-up, and PFS was calculated as the time to progression, death from any cause, or the last follow-up. Locoregional failures were defined as recurrences of primary tumor or regional lymph node, and distant metastasis were defined as disease progression excluding locoregional failure. Patients without evidence of progression were censored at the date of last follow-up or death. The treatment response evaluation was based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 [9]. Treatment-related toxicities were evaluated with Common Terminology Criteria for Adverse Events (CTCAE)4.0 criteria.

**Statistical analysis**

Survival time was estimated using the Kaplan-Meier method, and the difference was examined by the log-rank test. Hazard ratios (unadjusted and adjusted) were estimated using Cox proportional hazards model. This model with backward method was also performed.
to identify significant variables. Chi-square test was used for dichotomous data comparison between groups. Continuous variables were compared by using the Mann-Whitney U test. All tests were two-sided, and \( p \leq 0.05 \) was considered statistically significant. All the analyses were done using the SPSS software package (version 22.0, SPSS, Inc.)

**Results**

**Patient characteristics**

A total of 426 patients with stage III NSCLC were eligible for analysis, including 128 with SIB-IMRT and 298 with conventional IMRT. Patient and treatment characteristics of the two groups are summarized in Table 1. The median age for the entire cohort was 62 (range: 25–88) years, and 46% underwent concurrent chemoradiotherapy. SIB-IMRT group had more stage IIIIB disease (69.5% vs. 53%, \( p = 0.002 \)), larger planning treatment volumes (median: 504 ml vs. 402 ml, \( p < 0.001 \)), and a larger planning treatment volume/volume of lung ratio (median, 0.18 vs. 0.12, \( p < 0.001 \)). No significant difference was observed between the two groups regarding the distribution of age, gender, smokers, KPS, weight loss, histological classification, percentage of PET-CT staging, treatment modality, and radiation dose towards the PTV/PGTV (Table 1).

**Response and failure pattern**

The overall response rate was 81% for SIB-IMRT and 76.8% for conventional IMRT (\( p = 0.404 \)). Locoregional recurrence rates were similar between the two groups (51.6% vs. 44.6%, \( p = 0.306 \)). More details about failure pattern were shown in Table 2.

**Survival**

One hundred and eighty-two patients died (52 in the SIB-IMRT group; 132 in the conventional IMRT group), and 242 patients were still alive with a median follow-up time of 25 months (8-69 months) (SIB-IMRT group: 24 months; Conventional IMRT group: 26 months). The 1, 2, 3-year OS rate was 85.8, 60.4 and 49.4% for the SIB-IMRT group and 87.2, 59 and 46.9% for the conventional IMRT group. The difference regarding OS between the two arms was not statistically significant (\( p = 0.797 \), HR 0.959, 95%CI 0.695–1.232). The 1, 2, 3-year PFS rate was 64.7, 32.1 and 27.2% in the SIB-IMRT group and 68.3, 38.7 and 24.8% in the conventional group (\( p = 0.425 \), HR 1.11 95%CI 0.858–1.436). The median OS time (MST) were 34.5 and 31.7 months in the SIB-IMRT and conventional IMRT groups, with median PFS of 16.8 and 17.8 months, respectively. No significant difference was observed regarding LRFS (53% vs 45% at 3 years, \( p = 0.39 \)) and DMFS (53% vs. 48% at 3 years, \( p = 0.494 \)) between the two groups (Fig. 3).

The variables of age, gender, KPS, pathology, TNM stage, PET-staging, PTV, concurrent chemoradiotherapy, SIB-IMRT, and RT dose were included for multivariate analysis. The results showed that KPS (HR 0.463, 95%CI [0.269–0.796], \( p = 0.005 \)), PTV volume (HR 1.627, 95%CI [1.184–2.237], \( p = 0.003 \)) and concurrent chemoradiotherapy (HR 0.48, 95%CI [0.348–0.660], \( p < 0.001 \)) were independent factors affecting OS (Table 4).

**Dose and toxicities of OARs**

Dose of OARs and treatment-related reactions were collected. Higher lung doses (V5, V20, MLD), Heart dose (mean dose, V30) and spinal cord dose (maximal) were observed in patients receiving SIB-IMRT (Table 3). While patients with conventional IMRT got higher maximal dose of esophageal (\( p = 0.021 \)). No significant difference was observed in toxicities between the two groups, including radiation pneumonitis, esophagitis, hematologic toxicities and gastrointestinal reactions (Tables 4 and 5).

**Discussion**

Despite having more stage IIIIB disease (65% vs 50%), larger volume of PTV (median, 504 ml vs 402 ml), and a larger PTV/lung volume ratio (median, 0.18 vs. 0.12), the group of SIB-IMRT achieved similar efficacy and toxicities compared with conventional IMRT. The results demonstrated that SIB-IMRT might be an effective and safe treatment option for patients with LA-NSCLC. According to previous studies, the subclinical disease contained a lower tumor burden than gross tumor lesion, usually less than 10^8, and 45Gy–50Gy may effectively eradicate subclinical metastases [8, 10, 11]. The findings proved the theoretical feasibility of delivering a reduced dose to subclinical disease. Recently, several studies explored the application of SIB-IMRT in LA-NSCLC and the results were encouraging [12–14]. Although the dose delivered to CTV is reduced (median: 50.4–51.58Gy), the locoregional failures did not increase, with 2-year LRFS rates ranged from 62.5 to 66.1% [12, 13]. In the present study, the median dose delivered to PTV was much lower in the SIB-IMRT group (50.4Gy vs. 60Gy), but the 3-year LRFS rate was not compromising (53% vs. 45%, \( p = 0.39 \)). This result suggested that a conventionally fractionated dose of 50Gy might be sufficient to achieve good control in subclinical regions. A noteworthy feature of SIB-IMRT is that the technique can obtain highly conformal dose distribution with sharp dose gradients. Therefore, CBCT is needed to ensure the accurate tumor localization and dose delivery [15]. Considering the costs and time involved, we conducted five daily CBCTs in the first week followed by weekly imaging. But additional CBCTs were performed when imaging changes were detected requiring potential
| Characteristics          | SIB-IMRT group (n = 128) | Conventional IMRT group (n = 298) | P value |
|--------------------------|--------------------------|-----------------------------------|---------|
| Age (years)              |                          |                                   | 0.934   |
| ≤ 70                     | 110 (85.9%)              | 257 (86.2%)                       |         |
| > 70                     | 18 (14.1%)               | 41 (13.8%)                        |         |
| Gender                   |                          |                                   | 0.76    |
| Male                     | 101 (78.9%)              | 239 (80.2%)                       |         |
| Female                   | 27 (21.1%)               | 59 (19.8%)                        |         |
| KPS                      |                          |                                   | 0.213   |
| ≥ 80                     | 124 (96.9%)              | 280 (94%)                         |         |
| < 80                     | 4 (3.1%)                 | 18 (6%)                           |         |
| Smoking                  |                          |                                   | 0.214   |
| No                       | 37 (28.9%)               | 68 (22.8%)                        |         |
| Yes                      | 91 (71.1%)               | 230 (77.2%)                       |         |
| PET staging              |                          |                                   | 0.486   |
| Yes                      | 47 (36.7%)               | 99 (33.2%)                        |         |
| No                       | 81 (63.3%)               | 199 (66.8%)                       |         |
| Pathology                |                          |                                   | 0.251   |
| SCC                      | 74 (57.8%)               | 190 (63.8%)                       |         |
| ADE                      | 47 (36.7%)               | 86 (28.9%)                        |         |
| NSCLC                    | 7 (5.5%)                 | 22 (7.4%)                         |         |
| TNM stage                |                          |                                   | 0.002*  |
| IIIA                     | 39 (30.5%)               | 140 (47%)                         |         |
| IIIB                     | 89 (69.5%)               | 158 (53%)                         |         |
| T stage                  |                          |                                   | 0.009*  |
| T1                       | 11 (8.6%)                | 10 (3.4%)                         |         |
| T2                       | 50 (39.1%)               | 86 (28.9%)                        |         |
| T3                       | 31 (24.2%)               | 100 (33.6%)                       |         |
| T4                       | 36 (28.1%)               | 102 (34.2%)                       |         |
| N stage                  |                          |                                   | 0.001*  |
| N0                       | 1 (0.8%)                 | 14 (4.7%)                         |         |
| N1                       | 6 (4.7%)                 | 33 (11.1%)                        |         |
| N2                       | 48 (37.5%)               | 147 (49.3%)                       |         |
| N3                       | 73 (57%)                 | 104 (34.9%)                       |         |
| Treatment modality       |                          |                                   | 0.874   |
| RT alone                 | 11 (8.6%)                | 28 (9.4%)                         |         |
| Sequential CRT           | 59 (46.1%)               | 141 (47.3%)                       |         |
| Concurrent CRT           | 58 (45.3%)               | 129 (43.3%)                       |         |
| Prescribed dose (Gy)     |                          |                                   | 0.775   |
| ≥ 66                     | 11 (8.6%)                | 18 (6%)                           |         |
| 59–66                    | 98 (76.6%)               | 237 (79.5%)                       |         |
| 55–59                    | 12 (9.4%)                | 25 (8.4%)                         |         |
| 50–55                    | 7 (5.5%)                 | 18 (6%)                           |         |
| PTV volume (ml)          | 504 (128–960)            | 402 (51–890)                      | <0.001* |
| PTV/lung volume ratio    | 0.18 (0.04–0.43)         | 0.12 (0.01–0.32)                  | <0.001* |

KPS Karnofsky performance score, PET Positron emission tomography, TNM Tumor-node-metastasis, SCC Squamous cell carcinoma, ADE Adenocarcinoma, RT Radiotherapy, CRT Chemoradiotherapy, PTV Planning target volume

*p<0.05 was considered significant
treatment adjustment, in order to ensure the accuracy of radical radiotherapy.

In our study, a total of 128 patients received SIB-IMRT, with PGTV median dose of 59.92Gy (BED$_{10}$ = 72.74Gy). The results showed that the one, two, three-year OS rate was 85.8, 60.4 and 49.4%, respectively. The outcome made an improvement to OS compared with previous literature [12–14]. This was probably due to a higher proportion of patients receiving CCRT in our study than in other studies (45% vs. 27.6% & 35.5%). Meanwhile, the multivariate analysis indicated that CCRT was an independent factor predicting favorable OS. Thus standard CCRT should be applied for patients treated with SIB-IMRT, in order to achieve better survival.

Since the radiation dose delivered to subclinical areas was reduced, patients with SIB-IMRT are supposed to have better OAR spring. Xia et al. [16] demonstrated that plan-SIB resulted in better OAR spring (including

| Table 2 Comparison of failure patterns of patients between SIB-IMRT and conventional IMRT |
|-------------------------------------|-------------------------------------|------------------|
| SIB-IMRT group (n = 128) | Conventional IMRT group (n = 298) | P value |
| locoregional recurrence | 45 (35.2%) | 102 (34.2%) | 0.853 |
| distant-metastasis | 56 (43.8%) | 127 (42.6%) | 0.829 |
| locoregional+distant recurrence | 21 (16.4%) | 31 (10.4%) | 0.115 |

Wang et al. Radiation Oncology (2019) 14:106

Page 6 of 9

Fig. 3 Comparison of survival between SIB-IMRT and conventional IMRT in patients. a Overall survival, b Progression-free survival, c Locoregional-recurrence free survival, d Distant-metastasis free survival
Table 3. Comparison of radiation dose to OARs of patients between SIB-IMRT and conventional IMRT

| variables                          | SIB-IMRT median (range) | Conventional IMRT median (range) | P value |
|-----------------------------------|-------------------------|---------------------------------|---------|
| Radiation dose (Gy)               | 59.92 (50–70)           | 60 (50–70)                      | 0.627   |
| Lung V5 (%)                       | 60.98 (28.63–89.39)     | 52.29 (22.67–87.4)              | <0.001* |
| Lung V20 (%)                      | 25.26 (12.89–29.76)     | 22.82 (5.96–30.58)              | <0.001* |
| Lung V30 (%)                      | 17.7 (7.14–22.74)       | 17.35 (2.16–24.46)              | 0.113   |
| Mean lung dose (Gy)               | 15.10 (7.11–18.81)      | 14.08 (6.72–18.96)              | 0.001*  |
| Maximum esophageal dose (Gy)      | 65.26 (12.21–73.95)     | 64.86 (12.41–75.26)             | 0.021*  |
| Mean esophageal dose (Gy)         | 26.78 (7.88–50.63)      | 25.91 (4.31–50.63)              | 0.202   |
| Esophageal V40 (%)                | 36.75 (3.59–86.64)      | 35.47 (0–77.17)                 | 0.063   |
| Esophageal V50 (%)                | 26.28 (0.75–73.84)      | 28.25 (0–66.3)                  | 0.571   |
| Mean heart dose (Gy)              | 13.12 (8.53–31.62)      | 11.5 (29.6–31.69)               | 0.044*  |
| Heart V30 (%)                     | 15.51 (0.42–54.68)      | 12.92 (0–46.73)                 | 0.025*  |
| Heart V40 (%)                     | 9.21 (0–31.48)          | 8.05 (0–29.86)                  | 0.309   |
| Maximum spinal cord dose (Gy)     | 38.44 (30.26–64.87)     | 37.77 (9.12–42.42)              | 0.002*  |
| Maximum spinal cord PRV dose (Gy) | 42.98 (4.43–68.44)      | 43.11 (9.97–50.49)              | 0.96    |

V5 Volumes receiving more than 5Gy, V20 Volumes receiving more than 20Gy, V30 Volumes receiving more than 30Gy, V40 Volumes receiving more than 40Gy, V50 Volumes receiving more than 50Gy, PRV Planning organ at risk volume

*p<0.05 was considered significant

The present results indicate that it is a safe option to receive SIB-IMRT, and patients with large target volume have good tolerance to definitive radiotherapy with the technique.

Although the trial of RTOG 0617 failed to achieve the anticipated result, much interest remains in dose escalation. A retrospective analysis utilizing National Cancer Data Base enrolled 33,566 patients with stage III NSCLC treated by thoracic radiation, and the results showed that patients with dose of ≥66Gy had increased OS than those with dose of 59.4–60Gy (median: 21.1 vs 18.8 months) [18]. Dose-escalation is still a feasible tool to improve outcome if the toxicity can be well controlled [19]. SIB-IMRT seems to be a useful technique for dose-escalation, in which the increased dose was only delivered to GTV/PGTV [20]. A phase II trial conducted by Kong et al. [21] demonstrated that the dose-escalation using PET/CT-guided adaptive SIB-IMRT could achieve favorable local-regional control. Meanwhile, a retrospective study with small samples indicated that higher doses (>66Gy) to PGTV was associated with lower risk of distant metastasis [14]. In our study, the group of SIB-IMRT had larger target volume, and we supposed that most of them could not benefit from dose-escalation because of high risk of treatment-related toxicity. Therefore, only eleven patients received higher dose (≥66Gy) to PGTV. But the outcome was encouraging since only two patients (18.2%) had local-regional recurrence during follow-up. Further studies with larger samples are warranted to demonstrate the role of SIB-IMRT in dose-escalation for LA-NSCLC.

Table 4. Multivariate analysis for overall survival

| Characteristics                        | HR 95% CI | P value |
|----------------------------------------|-----------|---------|
| Age, years (>70≤70)                    | 0.279     |         |
| Gender (female: male)                  | 0.575     |         |
| KPS (280≤80)                           | 0.463 (0.269–0.796) | 0.005* |
| Pathology (ADESCC)                     | 0.374     |         |
| TNM stage (IIIB/IIIA)                  | 0.803     |         |
| PET staging (yes/no)                   | 0.836     |         |
| PTV (>535 cc≤535 cc)                   | 1.627 (1.184–2.237) | 0.003* |
| Concurrent chemoradiotherapy (yes/no)  | 0.48 (0.348–0.660) | <0.001* |
| SIB-IMRT (yes/no)                      | 0.504     |         |
| RT dose (≥59Gy≤59Gy)                   | 0.595     |         |

KPS Karnofsky performance score, ADE Adenocarcinoma, SCC Squamous cell carcinoma, TMN Tumor-node-metastasis, PET Positron emission tomography, PTV Planning target volume, RT Radiotherapy

*p<0.05 was considered significant
Because of the inherent flaws of a retrospective study, there are some limitations in the present study. Firstly, the imbalance of tumor size between the two arms may offset the benefit from SIB-IMRT. Secondly, the radiation dose and the chemotherapy regimens of the patients were not uniform. Last, because the health care system has not warranted coverage of PET for oncologic use, only 34.2% of the patients performed PET-CT before treatment in our study. But all the patients received comprehensive examinations to ensure the accuracy of TNM staging, including chest and abdominal CTs, brain MRI/CTs, bronchoscopies, and radionuclide bone scans.

**Conclusions**

In conclusion, this retrospective single institution study showed that SIB-IMRT might be an effective and safe option for patients with locally advanced NSCLC, especially for those with high risk of treatment-related toxicities. It offered patients with large tumor volume the chance to receive a more intense treatment. The value of dose-escalation using SIB technique is desirable. Future prospective clinical trials are warranted to confirm the efficacy of SIB-IMRT in NSCLC patients.

**Abbreviations**

CT: Computed tomograph; CTV: Clinical target volume; DMFS: Distant metastasis-free survival; GTV: Gross tumor volume; LRFS: Local-regional recurrence-free survival; MLD: Mean lung dose; NSCLC: Non-small cell lung cancer; OS: Overall survival; PFS: Progression-free survival; PGTV: Planning gross tumor volume; PTV: Planning target volume; SIB-IMRT: Simultaneous integrated boost intensity-modulated radiotherapy

**Acknowledgments**

Not applicable.

**Funding**

This trial was supported by the the CAMS Initiative for Innovative Medicine (grant number 2016-I2M-7-001), the National Key Projects of Research and Development of China (grant number 2016YFC0904600), and Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (grant number: 2018PT320111).

**Availability of data and materials**

The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

---

**Table 5** Comparison of radiation-related toxicities of patients between SIB-IMRT and conventional IMRT

| Adverse event | SIB-IMRT (n = 128) | | | | | | | | | | Conventional IMRT (n = 298) | | | | P value |
|--------------|-------------------|---|---|---|---|---|---|---|---|---|---------------------------------|---|---|---|---|
| Grade 2      | Grade 3           | Grade 4 | Grade 5 | | Grade 2 | Grade 3 | Grade 4 | Grade 5 | | |
| Pneumonitis  | 22 (17.2%)        | 3 (2.3%) | 0      | 5 (3.9%) | 45 (15.1%) | 3 (1.0%) | 0      | 5 (1.7%) | 0.337 |
| Esophagitis  | 32 (25%)          | 4 (3.1%) | 0      | 0         | 70 (23.5%) | 4 (1.3%) | 0      | 0         | 0.448 |
| Skin toxicity| 8 (6.3%)          | 1 (0.8%) | 0      | 0         | 25 (8.4%) | 2 (0.7%) | 0      | 0         | 0.738 |
| Leukopenia   | 30 (23.4%)        | 15 (11.7%) | 2 (1.6%) | 0 | 62 (20.8%) | 28 (9.4%) | 6 (2%) | 0 | 0.868 |
| Thrombocytopenia | 7 (5.5%) | 3 (2.3%) | 1 (0.8%) | 0 | 6 (2.0%) | 3 (1.0%) | 1 (0.3%) | 0 | 0.262 |
| Anemia       | 12 (9.4%)         | 0      | 0      | 0         | 18 (6%)  | 0      | 0      | 0         | 0.234 |
| Vomiting     | 3 (2.3%)          | 1 (0.8%) | 0      | 0         | 18 (6%)  | 0      | 0      | 0         | 0.069 |

---

**Authors’ contributions**

LHW and QFF were responsible for design of the project, quality assessment, and approval of the manuscript. DQW, TZ, NB, LHW, XW, LD, WQW, JBW, CYW, XTL, JPF, LFH, WJX performed data acquisition, the data analysis and the drafting of manuscript. QFF, NB, ZMZ, ZFX, JML, DFC, ZGH, JML and XZW critically reviewed the manuscript. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

This study was approved by the ethics committees of the institution. Written informed consent for scientific usage of clinical data was obtained from all patients.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**References**

1. Yang P, Allen MS, Aubry MC, et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest. 2005;128:452–62.
2. Bezjak A, Temin S, Franklin G, et al. Definitive and adjuvant radiotherapy in locally advanced non-small-cell lung Cancer: American Society of Clinical Oncology clinical practice guideline endorsement of the American Society for Radiation Oncology evidence-based clinical practice guideline. J Clin Oncol. 2015;33:2100–5.
3. Eberhardt WE, De Ruyscher D, Weder W, et al. 2nd ESMO consensus conference in lung Cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol. 2015;26:1573–88.
4. Liang J, Bi N, Wu S, et al. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial. Ann Oncol. 2015;26:1573–88.
5. Wang J, Zhou Z, Liang J, et al. Intensity-modulated radiation therapy may improve local-regional tumor control for locally advanced non-small cell lung Cancer compared with three-dimensional conformal radiation therapy. Oncologist. 2016;21:1530–7.
6. Chun SG, Hu C, Choy H, et al. Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung Cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial. J Clin Oncol. 2017;35:56–62.
7. Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-
8. Not applicable.
small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16:e87–99.

8. Kepka L, Maciejewski B, Withers RH. Does incidental irradiation with doses below 50 Gy effectively reduce isolated nodal failures in non-small-cell lung cancer: dose-response relationship. Int J Radiat Oncol Biol Phys. 2009;73:1391–6.

9. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.

10. Withers HR, Peters LJ, Taylor JM. Dose-response relationship for radiation therapy of subclinical disease. Int J Radiat Oncol Biol Phys. 1995;31:353–9.

11. Withers HR, Suwinski R. Radiation dose response for subclinical metastases. Semin Radiat Oncol. 1998;8:224–8.

12. Ji K, Zhao LJ, Liu WS, et al. Simultaneous integrated boost intensity-modulated radiotherapy for treatment of locally advanced non-small-cell lung cancer: a retrospective clinical study. Br J Radiol. 2014;87:20130562.

13. Xu Y, Zheng X, Bai X, et al. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in Chinese population: a retrospective study. Oncotarget. 2017;8:4984–92.

14. Fondevilla Soler A, Lopez-Guerra JL, Dzugashvili M, et al. Outcome and toxicity of intensity-modulated radiotherapy with simultaneous integrated boost in locally advanced non-small cell lung cancer patients. Clin Transl Oncol. 2017;19:469–77.

15. Ma L, Qiu B, Li Q, et al. An esophagus-sparing technique to limit radiation esophagitis in locally advanced non-small cell lung cancer treated by simultaneous integrated boost intensity-modulated radiotherapy and concurrent chemotherapy. Radiat Oncol. 2018;13:130.

16. Xia F, Zhou L, Yang X, et al. Is a clinical target volume (CTV) necessary for locally advanced non-small cell lung cancer treated with intensity-modulated radiotherapy? a dosimetric evaluation of three different treatment plans. J Thorac Dis. 2017;9:195–202.

17. Jiang ZQ, Yang K, Komaki R, et al. Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience. Int J Radiat Oncol Biol Phys. 2012;83:332–9.

18. Brower JV, Amini A, Chen S, et al. Improved survival with dose-escalated radiotherapy in stage II non-small-cell lung cancer: analysis of the National Cancer Database. Ann Oncol. 2016;27:1887–94.

19. Hudson A, Chan C, Woolf D, et al. Is heterogeneity in stage 3 non-small cell lung cancer obscuring the potential benefits of dose-escalated concurrent chemo-radiotherapy in clinical trials? Lung Cancer. 2018;118:139–47.

20. Yang W, Zeng B, Qiu Y, et al. A Dosimetric comparison of dose escalation with simultaneous integrated boost for locally advanced non-small-cell lung Cancer. Biomed Res Int. 2017;2017:9736362.

21. Kong FM, Ten Haken RK, Schipper M, et al. Effect of Midtreatment PET/CT-adapted radiation therapy with concurrent chemotherapy in patients with locally advanced non-small-cell Lung Cancer: a phase 2 clinical trial. JAMA Oncol. 2017;3:1358–65.